The Potential Utility of BTK Therapeutics to Manage Patients with Secondary Progressive Multiple Sclerosis

Mar 20, 2025

- Mar 19, 2026

0.75

Claim your AMA PRA Category 1 Credits or CNE Contact Hours

This course is available for logged in users only. Please login or register to take the course.

Des experts internationaux évaluent de nouvelles données sur l’inhibition de l’aldostérone...

Integrating Next-Generation Acid Suppression into Practical Algorithms for Gastroenterolog...

PCSK9 Inhibitors in Primary Prevention: A New Paradigm for Family Physicians